Finance

Lists
SGMT:NASDAQ
Sagimet Biosciences Inc
USD 8,93
+0,11%
(+0,010) 1D
USD 8,90
-0,34% (-0,030)
After hours
Closed: 9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGMT...
Open
USD 8,84
High
USD 9,05
Low
USD 8,78
Mkt. cap
629,86 m
Avg. vol.
1,29 m
Volume
763,53 k
52-wk high
USD 11,45
52-wk low
USD 4,50
EPS
-USD 1,28
Beta
3,46
Shares outstanding
70,34 m
No. of employees
16
Open
USD 8,84
High
USD 9,05
Low
USD 8,78
Mkt. cap
629,86 m
Avg. vol.
1,29 m
Volume
763,53 k
52-wk high
USD 11,45
52-wk low
USD 4,50
EPS
-USD 1,28
Beta
3,46
Shares outstanding
70,34 m
No. of employees
16
News stories
From web sources and news partners
About Sagimet Biosciences Inc
CEO-
Employees16
Founded2006
HeadquartersSan Mateo, Kalifornië, Verenigde State van Amerika
Sector-
Websitesagimet.com
Analyst ratings
Based on 12 analysts giving stock ratings to SGMT in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
1
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for SGMT in the last 3 months.
Highest
Current USD 8,93
USD 56,00 (+527,10%)
Average
USD 28,46 (+218,70%)
Lowest
USD 7,00 (-21,61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
USD 29,00
+224,7%
10/05/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
USD 26,00
+191,2%
10/01/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
10/01/2026
Andrea Newkirk
Goldman Sachs
Sell
Maintained
USD 7,00
-21,6%
09/30/2026
Jay Olson
Oppenheimer
Buy
Maintained
USD 38,00
+325,5%
10/01/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
USD 56,00
+527,1%
10/01/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
USD 25,10
+181,1%
10/01/2026
Yun Zhong
Wedbush
Buy
Maintained
USD 28,00
+213,5%
10/01/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
USD 27,00
+202,4%
10/01/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
USD 28,00
+213,5%
09/30/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
USD 31,00
+247,1%
09/27/2026
Eliana Merle
Barclays
Buy
Upgraded
USD 18,00
+101,6%
09/09/2026
Ritu Baral
TD Cowen
Buy
Maintained
USD 21,00
+135,2%
05/12/2026
Unknown Analyst
Rodman & Renshaw
Buy
Initiated
USD 28,00
+213,5%
03/26/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
USD 28,00
+213,5%
03/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9,73 m
6,73 m
7,00 m
11,54 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,60 m
4,03 m
4,72 m
4,28 m
Operating expense
14,33 m
10,76 m
11,71 m
15,82 m
Total operating expenses
14,33 m
10,76 m
11,71 m
15,82 m
Operating income
-14,33 m
-10,76 m
-11,71 m
-15,82 m
Other non operating income
-
-
-
-
EBT including unusual items
-12,91 m
-9,57 m
-10,65 m
-13,95 m
EBT excluding unusual items
-12,91 m
-9,57 m
-10,65 m
-13,95 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,91 m
-9,57 m
-10,65 m
-13,95 m
Net profit margin
-
-
-
-
Earnings per share
-0,40
-0,29
-0,33
-0,26
Interest and investment income
1,43 m
1,20 m
1,06 m
1,86 m
Interest expense
-
-
-
-
Net interest expenses
1,43 m
1,20 m
1,06 m
1,86 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme